Pfizer in talks to merge off-patent drugs business with Mylan

  • 📰 Reuters
  • ⏱ Reading Time:
  • 16 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 10%
  • Publisher: 97%

Indonesia Berita Berita

Indonesia Berita Terbaru,Indonesia Berita utama

Pfizer Inc is in talks to merge its off-patent drugs business with Mylan NV in a...

) in a stock deal, the Wall Street Journal reported on Saturday, citing people familiar with the matter.

Mylan shareholders would receive a little more than 40% of the newly formed entity, with Pfizer shareholders receiving the remainder, the Journal said, adding Pfizer would also get about $12 billion in proceeds from a new sale of debt.Reporting by Maria Ponnezhath in Bengaluru; Editing by Mark Potter

 

Terima kasih atas komentar Anda. Komentar Anda akan dipublikasikan setelah ditinjau.

Further consolidation that will result in increased drug prices. Republicans will say this is free market principals. Americans will blame Democrats either way.

Berita ini telah kami rangkum agar Anda dapat membacanya dengan cepat. Jika Anda tertarik dengan beritanya, Anda dapat membaca teks lengkapnya di sini. Baca lebih lajut:

 /  🏆 2. in İD

Indonesia Berita Terbaru, Indonesia Berita utama

Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.

Pfizer Nears Deal to Combine off-Patent Drug Business With MylanPfizer is in talks to merge its off-patent drugs business with generic drugmaker Mylan, in a deal that would create a giant global seller of lower-priced medicines. Sr. lopez atención sr. lopez..... Se necesitán medicamentos en méxico... Atención jonathanrockoff so that they can raise the price? Ha ha ha. Lower prices. Ha ha ha. Methinks I've heard that before. Ha ha ha.
Sumber: WSJ - 🏆 98. / 63 Baca lebih lajut »

Pfizer Nears Deal to Combine off-Patent Drug Business With MylanPfizer is in talks to merge its off-patent drugs business with generic drugmaker Mylan, in a deal that would create a giant global seller of lower-priced medicines. Sr. lopez atención sr. lopez..... Se necesitán medicamentos en méxico... Atención jonathanrockoff so that they can raise the price? Ha ha ha. Lower prices. Ha ha ha. Methinks I've heard that before. Ha ha ha.
Sumber: WSJ - 🏆 98. / 63 Baca lebih lajut »

There's no business like the arms business: Here's how the top US defense companies did in Q2 earningsNobody spends money on arms like the United States, and it shows in the bottom lines of the biggest defense contractors. 'While the companies’ quarterly performances remained strong, collectively their stocks were largely unchanged. The iShares U.S. Aerospace and Defense ETF was slightly higher for this week after the companies reported. So far this year the benchmark ETF is up nearly 26 percent.'
Sumber: CNBC - 🏆 12. / 72 Baca lebih lajut »